Christina Peroutka1,2, Jacqueline Salas1, Jacquelyn Britton2, Juliet Bishop2, Lisa Kratz2,3, Maureen M Gilmore1, Jill A Fahrner1,2, W Christopher Golden4, Tao Wang5,6. 1. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Kennedy Krieger Institute, Baltimore, MD, USA. 4. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cgolden@jhmi.edu. 5. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. twang9@jhmi.edu. 6. Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. twang9@jhmi.edu.
Abstract
BACKGROUND: Deleterious mutations in cytosolic leucine-tRNA synthetase (LARS) cause infantile liver failure syndrome, type 1 (ILFS1), a recently recognized, rare autosomal recessive disorder (OMIM151350). Only six families with ILFS1 have been reported in the literature. Patients with ILFS1 are typically diagnosed between 5 and 24 months of age with failure to thrive, developmental delays, encephalopathy, microcytic anemia, and chronic liver dysfunction with recurrent exacerbations following childhood illnesses. Neonatal manifestations of this disorder have not been well documented. CASE REPORT: We report a premature female newborn with intrauterine growth restriction, failure to thrive, congenital anemia, anasarca, and fulminant liver failure leading to lethal multiple organ failure. Liver failure in this infant was characterized by a disproportionate impairment of liver synthetic function, including severe coagulopathy and hypoalbuminemia without significant defects in liver detoxification or evidence of hepatocellular injury during early phase of the disease. Whole-exome sequencing of child-parent trio identified two inherited missense mutations in LARS in this patient. One, c.1292T>A; p.Val431Asp, has been reported in patients with ILFS1, while the other, c.725C>T; p.Pro242Leu, is novel. Both mutations involve amino acid residues in the highly conserved editing domain of LARS, are predicted to be functionally deleterious, and presumably contribute to the clinical manifestations in this patient. CONCLUSION: This is the first case documenting neonatal manifestation of ILFS1, highlighting early, severe, and disproportionate defects in liver synthetic function. Timely diagnosis of ILFS1 is crucial to guide critical clinical management and improve outcomes of this rare and potentially life-threatening disorder.
BACKGROUND: Deleterious mutations in cytosolic leucine-tRNA synthetase (LARS) cause infantile liver failure syndrome, type 1 (ILFS1), a recently recognized, rare autosomal recessive disorder (OMIM151350). Only six families with ILFS1 have been reported in the literature. Patients with ILFS1 are typically diagnosed between 5 and 24 months of age with failure to thrive, developmental delays, encephalopathy, microcytic anemia, and chronic liver dysfunction with recurrent exacerbations following childhood illnesses. Neonatal manifestations of this disorder have not been well documented. CASE REPORT: We report a premature female newborn with intrauterine growth restriction, failure to thrive, congenital anemia, anasarca, and fulminant liver failure leading to lethal multiple organ failure. Liver failure in this infant was characterized by a disproportionate impairment of liver synthetic function, including severe coagulopathy and hypoalbuminemia without significant defects in liver detoxification or evidence of hepatocellular injury during early phase of the disease. Whole-exome sequencing of child-parent trio identified two inherited missense mutations in LARS in this patient. One, c.1292T>A; p.Val431Asp, has been reported in patients with ILFS1, while the other, c.725C>T; p.Pro242Leu, is novel. Both mutations involve amino acid residues in the highly conserved editing domain of LARS, are predicted to be functionally deleterious, and presumably contribute to the clinical manifestations in this patient. CONCLUSION: This is the first case documenting neonatal manifestation of ILFS1, highlighting early, severe, and disproportionate defects in liver synthetic function. Timely diagnosis of ILFS1 is crucial to guide critical clinical management and improve outcomes of this rare and potentially life-threatening disorder.
Authors: Jillian P Casey; Paul McGettigan; Niamh Lynam-Lennon; Michael McDermott; Regina Regan; Judith Conroy; Billy Bourke; Jacintha O'Sullivan; Ellen Crushell; SallyAnn Lynch; Sean Ennis Journal: Mol Genet Metab Date: 2012-04-26 Impact factor: 4.797
Authors: Shikha S Sundaram; Estella M Alonso; Michael R Narkewicz; Song Zhang; Robert H Squires Journal: J Pediatr Date: 2011-05-31 Impact factor: 4.406
Authors: Jillian P Casey; Suzanne Slattery; Melanie Cotter; A A Monavari; Ina Knerr; Joanne Hughes; Eileen P Treacy; Deirdre Devaney; Michael McDermott; Eoghan Laffan; Derek Wong; Sally Ann Lynch; Billy Bourke; Ellen Crushell Journal: J Inherit Metab Dis Date: 2015-04-28 Impact factor: 4.982
Authors: Molly E Kuo; Arjan F Theil; Anneke Kievit; May Christine Malicdan; Wendy J Introne; Thomas Christian; Frans W Verheijen; Desiree E C Smith; Marisa I Mendes; Lidia Hussaarts-Odijk; Eric van der Meijden; Marjon van Slegtenhorst; Martina Wilke; Wim Vermeulen; Anja Raams; Catherine Groden; Shino Shimada; Rebecca Meyer-Schuman; Ya Ming Hou; William A Gahl; Anthony Antonellis; Gajja S Salomons; Grazia M S Mancini Journal: Am J Hum Genet Date: 2019-02-26 Impact factor: 11.025